Article · Wikipedia archive · Last revised Jul 27, 2026

Etripamil

Etripamil, sold under the brand name Cardamyst, is a medication used for the treatment of paroxysmal supraventricular tachycardia. It is a calcium channel blocker. It is used as a nasal spray.

Last revised
Jul 27, 2026
Read time
≈ 1 min
Length
310 w
Citations
12
Source
Wikipedia ↗
Etripamil
Clinical data
Trade namesCardamyst
Other namesMSP-2017
AHFS/Drugs.comcardamyst
License data
Routes of
administration		Intranasal
Drug classCalcium channel blocker
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC27H36N2O4
Molar mass452.595 g·mol−1
3D model (JSmol)
  • COC(=O)C1=CC(CCN(C)CCC[C@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)=CC=C1
  • InChI=1S/C27H36N2O4/c1-20(2)27(19-28,23-11-12-24(31-4)25(18-23)32-5)14-8-15-29(3)16-13-21-9-7-10-22(17-21)26(30)33-6/h7,9-12,17-18,20H,8,13-16H2,1-6H3/t27-/m0/s1
  • Key:VAZNEHLGJGSQEL-MHZLTWQESA-N
  • Key:JHOAIMAMBNLIMD-YCBFMBTMSA-N

Etripamil, sold under the brand name Cardamyst, is a medication used for the treatment of paroxysmal supraventricular tachycardia.1 It is a calcium channel blocker.1 It is used as a nasal spray.1

Etripamil was approved for medical use in the United States in December 2025.2

Medical uses

Etripamil is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm.134

Pharmacology

Mechanism of action

Etripamil is a voltage-dependent L-type calcium channel inhibitor.3

Society and culture

Etripamil was approved for medical use in the United States in December 2025.2

Names

Etripamil is the international nonproprietary name.5

Etripamil is sold under the brand name Cardamyst.1

References

References

  1. "Cardamyst (etripamil) nasal spray" (PDF). Milestone Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. December 2025.
  2. "Milestone Receives FDA Approval of Cardamyst (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)" (Press release). Milestone Pharmaceuticals. 13 December 2025. Retrieved 16 December 2025 – via GlobeNewswire News Room.
  3. Calvert P, Gupta D (2024). "Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia". Future Cardiology. 20 (3): 163–170. doi:10.1080/14796678.2024.2342651. PMC 11216497. PMID 38717391.
  4. Jha M, Song D, Kung A, Lo S, Sacher A, Ang SP, et al. (May 2025). "Efficacy and Safety of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia: Meta-Analysis of Randomized Controlled Trials". Journal of Clinical Medicine. 14 (11): 3720. doi:10.3390/jcm14113720. PMC 12155871. PMID 40507484.
  5. World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl:10665/331046.
External links
  • Clinical trial number 03464019 for "Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). (NODE-301)" at ClinicalTrials.gov